Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have received a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $10.40.

A number of equities analysts have issued reports on IRWD shares. StockNews.com cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Finally, Leerink Partners initiated coverage on Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 price objective for the company.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other news, CFO Sravan Kumar Emany sold 11,001 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the transaction, the chief financial officer now owns 309,572 shares in the company, valued at $1,263,053.76. This trade represents a 3.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 12.90% of the company’s stock.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in IRWD. KBC Group NV boosted its holdings in shares of Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 3,198 shares in the last quarter. First Dallas Securities Inc. purchased a new position in Ironwood Pharmaceuticals during the 2nd quarter valued at about $73,000. Diversified Trust Co bought a new stake in Ironwood Pharmaceuticals during the third quarter worth about $52,000. Wolverine Trading LLC purchased a new stake in Ironwood Pharmaceuticals in the third quarter worth about $51,000. Finally, Algert Global LLC bought a new position in shares of Ironwood Pharmaceuticals during the second quarter valued at approximately $93,000.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD stock opened at $4.43 on Wednesday. The business has a 50-day moving average of $4.00 and a 200 day moving average of $4.81. Ironwood Pharmaceuticals has a 1-year low of $3.06 and a 1-year high of $15.70. The stock has a market capitalization of $708.92 million, a PE ratio of -147.67 and a beta of 0.41.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The company had revenue of $91.60 million for the quarter, compared to analysts’ expectations of $91.22 million. During the same period last year, the company posted $0.12 EPS. The business’s revenue for the quarter was down 19.4% compared to the same quarter last year. Analysts anticipate that Ironwood Pharmaceuticals will post 0.08 EPS for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.